FIND’s Post

As we navigate the aftermath of COVID-19, the IPPS report outlines actions for all sectors to increase preparedness, and renew focus in 2024 on diagnostics, therapeutics, regulatory harmonisation and sustainable clinical trials. Explore the insights here: https://lnkd.in/e5q2SjTA #FIND#Diagnostics#IVD#IPPS

Accha! "…only a deep understanding of what patients are going through, from early diagnosis to post-treatment monitoring, will make pharma companies trusted partners with the capability to adequately accompany patients through their clinical trial experience…". In addition, I am glad to see the following two among the imperatives for creating a future-ready Next-Generation Therapeutics organization: (1) "Work hand in hand with patients and policymakers", and (2) "Provide end-to-end support" to patients. https://lnkd.in/eqFZCdhB #patientengagement #patientcentricity #patientcenteredcare #medicalaffairs

Qatar Investment Authority (QIA) dedicated to healthtech by investing in innovative healthcare companies as well as funds Latest investment in startups: 🇺🇸 Outpace Bio (Aug 2024, Series B, $144 million, CEO Marc Lajoie) is a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors 🇺🇸 Iambic Therapeutics (Jun 2024, Series B+, $50 million, CEO Thomas Miller) is a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform 🇬🇧 Autolus Therapeutics (Feb 2024, equity investment, $250 million + $350 million, CEO Christian Itin) is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies 🇮🇳 Global Dental Services (Nov 2023, equity investment, $50 million, CEO Amarinder Singh) India's largest tech-enabled-dental-platform that operates more than 400 company-owned and company-operated dental clinics under the “Clove Dental" banner 🇺🇸 BridgeBio (Sep 2023, PIPE financing, $250 million, CEO Neil Kumar) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers 🇺🇸 Star Therapeutics (Sep 2023, Series C, $90 million, CEO Adam Rosenthal) is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need Contact QIA Healthcare Investment Team https://lnkd.in/ezbyKmtM Investment in funds: 🇶🇦🤝🇫🇷 Future French Champions (May 2024, €300 million) is a joint-venture between Qatar Investment Authority (QIA) and Bpifrance that has invested almost €600 million over two phases to boost economic growth and innovation in France. As the 3rd phase, they have announced intention to increase their commitment by up to another €300 million once the current commitment is fully deployed.  The strategic priorities:  🤖 Artificial Intelligence (AI) 🏿 Semiconductors ⚛️ Quantum Computing 🏥 Healthcare 🚀 Aerospace ⚡ Energy Transition This year, QIA also announced (https://lnkd.in/eARVkTBT) the creation of a $1 billion VC fund of funds to support the development of the local entrepreneurial ecosystem. The sectors of interest: 🖥 Technology 🏥 Healthcare 💳 Fintech 🎓 Edtech Contact QIA Funds Investment Team https://lnkd.in/eRVD5r7k 

Digital therapeutics: value, evidence, and access in the Asia-Pacific region https://lnkd.in/gxufRWnU In this article, we explore the current developments and trends in access for digital therapeutics in the Asia-Pacific region, including the role of superapps in navigating the diverse regulatory and reimbursement landscapes. https://lnkd.in/gxufRWnU #HEOR #MarketAccess #WeAreAvalereHealth

In this K-Cast, Diana Brixner, PhD, FAMCP, explores how the US FDA and industry associations define, identify and evaluate digital therapeutics, including nonprescription digital tools and interventions. Watch the episode here: https://bit.ly/3VyfxKV #ManagedCare #DigitalHealth Diana Brixner

We will never have enough clinicians to meet the need for mental health services. We need scalable solutions that are proven to work. Europe is rapidly increasing access to digital treatments and other regions will soon follow. Our very own Will Goddard wrote a piece about how we can address mental health needs worldwide through our digital treatments. Worth a read. #mentalhealth #digitaltreatments

❝Just as the pharmaceutical industry successfully scaled access to medicines, so too can the digital therapeutics industry scale access to psychological care to meet global needs.❞ Digital therapeutics have the potential to completely transform mental healthcare worldwide, and Europe is uniquely positioned to shape how they will be adopted. With this opportunity, however, comes a duty to healthcare providers and patients alike. Europe must lead the way by setting a high standard for what defines digital therapeutics and their implementation. In this new Critical Thinking article, Will Goddard, UK managing director Big Health, highlights the need for collaboration among European countries and defines the necessary parameters for regulation. ️⤵️ Read the full article below. #CriticalThinking #SustainableLivelihoods #DigitalHealth #MentalHealth 

You wouldn’t give your mother or your friend a medicine that ‘might’ work – so why would you do the same with an app? I wrote a piece for Friends of Europe on what must happen for patients across the world to benefit from digital therapeutics. I'm convinced the answer is higher standards for suppliers. That might seem counterintuitive - higher standards & regulation don't often lead to rapid adoption. However, this approach is essential to avoid adoption for adoption’s sake. Higher adoption is only good news if the digital therapeutics we adopt benefit patients; clearer standards are fundamental to that.

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/gWCF2r2b #PrecisionOncology #Regulatory #NovelInsights

Client feedback helps inspire our teams to constantly improve and innovate the way we research and refine your potentially life-saving therapeutics. Watch as Marie-Helene Raigneau elaborates on the impact of your feedback. #WeAreAltasciences #WhatMotivatesMe #CustomerCentricity